Methods and materials for treating cancer (e.g., melanoma) in a subject and for improving efficacy of adoptive immune cell therapy are described. The methods can include administering immune cells (e.g., chimeric antigen receptor T cells or tumor-infiltrating lymphocytes) having reduced expression of a VPS39 polypeptide to the subject.

The present invention concerns methods and compositions for evoking protective immune responses against pathogen infection or cancer. In certain embodiments, the methods and compositions comprise a lymphangiogenesis inducer and an antigen.

The present invention concerns methods and compositions for evoking protective immune responses against pathogen infection or cancer. In certain embodiments, the methods and compositions comprise a lymphangiogenesis inducer and an antigen.

The present invention relates to the field of medicine. It more particularly relates to peptides, microvesicles containing such peptides, compositions containing same, in particular vaccine, and methods for stimulating an immune response in a subject.

A set of target peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of disease cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., cancer, (b) to function as immunotherapeutics in adoptive T cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex.

Disclosed are methods for treating, inhibiting, reducing, and/or preventing cancers (such as, for example melanoma) and/or metastasis (such as, for example metastatic melanoma) comprising administering to a subject a L-fucose and an anti-androgen therapy.

Disclosed are methods for treating, inhibiting, reducing, and/or preventing cancers (such as, for example melanoma) and/or metastasis (such as, for example metastatic melanoma) comprising administering to a subject a L-fucose and an anti-androgen therapy.

The present disclosure relates to methods, cells, and compositions for preparing T cell populations and compositions for adoptive cell therapy. In particular, provided herein are methods for efficiently expanding and activating T cell populations for genetic engineering and adoptive T cell immunotherapies. Also provided are cells and compositions produced by the methods and methods of their use.

The present invention relates to engineered extra-cellular vesicle internalizing receptors that have the ability to enhance uptake, processing, and presentation to T-cells of tumor-associated antigens by an antigen-presenting cell. It further relates to vectors or antigen presenting cells expressing said receptors, composition and uses thereof for the prevention and/or treatment of a cancer.

The present invention provides a method of generating a population of tumour-infiltrating T cells, said method comprising administering to a subject a positively charged amphipathic amino acid derivative, peptide or peptidomimetic which is able to lyse tumour cell membranes and then collecting a cellular sample from a tumour within said subject and separating T cells therefrom. The present invention further provides a method of generating a population of tumour-infiltrating T cells, said method comprising separating T cells from a cellular tumour sample taken from a subject treated with a positively charged amphipathic amino acid derivative, peptide or peptidomimetic which is able to lyse tumour cell membranes and optionally culturing said T cells. The present invention also provides the tumour-infiltrating T cells described above for use in treating tumour cells or preventing or reducing the growth, establishment, spread, or metastasis of a tumour.